Abstract
Retinoblastoma is the most common intraocular tumor in children. Current management includes broad-based treatments such as chemotherapy, enucleation, laser therapy, or cryotherapy. However, therapies that target specific pathways important for retinoblastoma progression could provide valuable alternatives for treatment. MicroRNAs are short, noncoding RNA transcripts that can regulate the expression of target genes, and their aberrant expression often facilitates disease. The identification of post-transcriptional events that occur after the initiating genetic lesions could further define the rapidly aggressive growth displayed by retinoblastoma tumors. In this study, we used two phenotypically different retinoblastoma cell lines to elucidate the roles of miRNA-31 and miRNA-200a in tumor proliferation. Our approach confirmed that miRNAs-31 and -200a expression is significantly reduced in human retinoblastomas. Moreover, overexpression of these two miRNAs restricts the expansion of a highly proliferative cell line (Y79), but does not restrict the growth rate of a less aggressive cell line (Weri1). Gene expression profiling of miRNA-31 and/or miRNA-200a-overexpressing cells identified differentially expressed mRNAs associated with the divergent response of the two cell lines. This work has the potential to enhance the development of targeted therapeutic approaches for retinoblastoma and improve the efficacy of treatment.
Original language | English (US) |
---|---|
Article number | e0138366 |
Journal | PloS one |
Volume | 10 |
Issue number | 9 |
DOIs | |
State | Published - Sep 17 2015 |
Funding
The authors would like to thank Nancy Su, Jatuphon Chaiseesiri, and William Goosens for technical assistance and Elaine Santos for administrative assistance. This work was supported by the Illinois Department of Public Health–Excellence in Academic Medicine Award (to N.A.L.), National Institutes of Health/National Cancer Institute grant R21 CA167225 (to N.A.L), National Institute of General Medical Sciences grant R25 GM079300 (to V.M), and the Research to Prevent Blindness Inc. NY, NY (to P.B.).
ASJC Scopus subject areas
- General